![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Vertex Pharmaceuticals | Home
Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
Vertex Pharmaceuticals | Our Company
Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.
Vertex Pharmaceuticals | Our Science | R&D Pipeline
Vertex Pharmaceuticals is focused on discovering, developing and producing innovative medicines so people with serious diseases can lead better lives.
Vertex Pharmaceuticals | Home
Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
Vertex Pharmaceuticals | Our Science
At Vertex, we believe "impossible" is just a starting point. We’re not limited by what we’ve done before. We’re leveraging our robust toolkit of technologies and expertise to tackle serious diseases like cystic fibrosis, sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes and more.
Investor Relations | Vertex Pharmaceuticals
The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
Vertex Pharmaceuticals | Our Company
Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.
Press Releases - Vertex Pharmaceuticals Newsroom
2024年12月20日 · BOSTON --(BUSINESS WIRE)--Jan. 27, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people living with serious diseases, with a focus on specialty markets.
Newsroom | Vertex Pharmaceuticals Newsroom
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain